FocalTherics (NASDAQ:FOCL) Posts Quarterly Earnings Results, Beats Estimates By $0.08 EPS

FocalTherics (NASDAQ:FOCL) announced its quarterly earnings results on Thursday. The company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.08, FiscalAI reports. The company had revenue of $9.83 million during the quarter. FocalTherics had a negative return on equity of 248.00% and a negative net margin of 56.26%.

Here are the key takeaways from FocalTherics’ conference call:

• Third-quarter HIFU revenue rose 26% to $9.8 million, but three expected system sales slipped because of hospital approval and financing delays. The company narrowed 2026 revenue guidance to $50 million–$52 million, from $50 million–$54 million, while saying the delayed sales are expected to close in Q4.
• U.S. Focal One procedure volumes grew 32% year over year, and treatment-driven revenue increased 24%; the worldwide installed base reached 192 systems. Management said utilization growth should continue as established programs expand, while noting new centers take time to ramp.
• Access and reimbursement advanced: France has universal national coverage for Focal One, and several major U.S. commercial payers now cover HIFU as salvage treatment after radiation failure, following an NCCN recommendation upgrade.
• Gross margin improved to 51.4% from 46.6%, but operating expenses rose to $12.8 million and operating loss widened to $7.8 million. Cash and equivalents increased to $56.3 million after the August equity offering.
• FocalTherics is extending Focal One into other indications: three European centers are treating commercial patients for endometriosis, while its BPH program remains in clinical development. The company expects data from the HIFUSA randomized trial early next year.

FocalTherics Price Performance

NASDAQ FOCL traded down $0.52 during trading on Friday, reaching $3.73. The company’s stock had a trading volume of 289,586 shares, compared to its average volume of 70,913. The company has a market capitalization of $139.98 million, a PE ratio of -3.62 and a beta of -0.02. The company has a debt-to-equity ratio of 1.79, a current ratio of 1.60 and a quick ratio of 1.38. The stock has a fifty day moving average of $4.25. FocalTherics has a one year low of $1.82 and a one year high of $6.40.

Wall Street Analyst Weigh In

Several research analysts have commented on the company. Weiss Ratings restated a “sell (d-)” rating on shares of FocalTherics in a research note on Monday, August 17th. Wall Street Zen downgraded shares of FocalTherics from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Mizuho initiated coverage on shares of FocalTherics in a research report on Friday, July 17th. They issued an “outperform” rating and a $15.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of FocalTherics in a research note on Tuesday, August 25th. Finally, Piper Sandler reaffirmed a “neutral” rating and set a $4.00 price objective on shares of FocalTherics in a research note on Friday, August 14th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $9.67.

Insider Transactions at FocalTherics

In other FocalTherics news, Director Joshua Levine acquired 10,000 shares of the business’s stock in a transaction dated Friday, August 14th. The stock was bought at an average price of $4.75 per share, with a total value of $47,500.00. Following the completion of the acquisition, the director owned 45,000 shares of the company’s stock, valued at $213,750. This trade represents a 28.57% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director David R. Horn acquired 10,000 shares of the firm’s stock in a transaction that occurred on Friday, August 14th. The stock was bought at an average price of $4.75 per share, for a total transaction of $47,500.00. Following the completion of the transaction, the director owned 10,000 shares of the company’s stock, valued at $47,500. The trade was a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders have bought 116,000 shares of company stock worth $551,000. 10.10% of the stock is owned by insiders.

Hedge Funds Weigh In On FocalTherics

A hedge fund recently bought a new stake in FocalTherics stock. Lido Advisors LLC purchased a new position in FocalTherics (NASDAQ:FOCL) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 10,654 shares of the company’s stock, valued at approximately $40,000. 62.74% of the stock is owned by institutional investors.

FocalTherics Company Profile

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.